ABBOTT LABORATORIES WKN: 850103 ISIN: US0028241000 Kürzel: ABT Forum: Aktien Thema: Hauptdiskussion

Buy and hold

der dip ist apatestens in eibem monat vergessen vlt sogar diese woche

Das sehe ich auch so, zu diesen Kursen muss man eigentlich nachkaufen

Q3 2025 Earnings Snapshot** - **Adj EPS**: $1.30 (met est.) ✅ - **Revenue**: $11.37B (missed est. $11.4B) ❌; +6.9% YoY - **Organic Sales Growth**: +5.5% (+7.5% ex-COVID testing) **2025 Guidance (Reaffirmed)**: - Organic Sales Growth: 7.5-8.0% (ex-COVID); 6.0-7.0% (incl. COVID) - Adj EPS: $5.12-$5.18 (narrowed range) **Q3 Metrics**: - Reported Operating Margin: 18.1% - Adj Operating Margin: 23.0% (+40 bps YoY) - U.S. Sales: $4.30B (+2.3% YoY) - International Sales: $7.07B (+9.9% YoY) **Segment Performance**: - **Nutrition**: $2.15B (+4.2% reported, +4.0% organic) - Pediatric: $977M (+2.3% reported) - Adult: $1.18B (+5.8% reported) - **Diagnostics**: $2.25B (-6.6% reported, +0.4% organic ex-COVID) - COVID-19 Testing: $69M (vs. $265M Q3'24) - Core Lab: $1.36B (+3.8% reported) - Rapid Diagnostics: $600M (-27.3% reported) - **Established Pharma**: $1.51B (+7.5% reported, +7.1% organic) - **Medical Devices**: $5.45B (+14.8% reported, +12.5% organic) - Diabetes Care: $2.06B (+19.3% reported) - CGM Sales: $2.0B (+20.5% reported) - Electrophysiology: $705M (+15.6% reported) **CEO Robert Ford**: "Q3 reflects consistent, high-quality results driven by our strong product pipeline, ensuring durable value for shareholders."

$ABT | Abbott Labs Q2 2025 Earnings - Net Sales $11.14B (est $11.06B) - Adj EPS $1.26 (est $1.25) - Organic Sales +6.9% (est +7.03%) - Sees Q3 Adj EPS $1.28 To $1.32 (est $1.34) - Sees FY Adj EPS $5.10 To $5.20, Saw $5.05 To $5.25

$ABT | Abbott Labs Q1 2025 Earnings - Adj EPS $1.09 (est $1.07) - Net Sales $10.36B (est $10.4B) - Reaffirms FY Guidance - Still Sees FY Adj EPS $5.05 To $5.25 (est $5.15) - Sees Q2 Adj EPS $1.23 To $1.27 (est $1.25)

Aus meiner Sicht Ausbruch nach oben, nach längerer Seitwärtsphase

🥳🚀😂

Abbott Labs reports robust Q4 & 2024 results: $11B Q4 sales (+7.2%), $42B full-year (+4.6%). Strong organic growth in base business. 2025 outlook positive with 7.5-8.5% organic sales growth projected. 404th consecutive quarterly dividend declared

ABBOTT, RECKITT NOT LIABLE IN TRIAL OVER CLAIMS THAT PREMATURE INFANT FORMULA CAUSED DEBILITATING ILLNESS, JURY FINDS

Abbott Laboratories reported Q3 revenues of $10.63 billion: a +5% Y/Y growth and ~1% above consensus estimates. 🔹Operating margin expanded 0.51 p.p. Y/Y to 23.4%, roughly in line with the 23.4% expectation. 🔹EPS (non-GAAP) was $1.21: a +6% Y/Y increase, and 1% above consensus estimates.

#Abbott Laboratories $ABT #Earnings: - Q3 Non-GAAP EPS of $1.21 beats by $0.01. - Revenue of $10.64B (+4.9% Y/Y) beats by $90M.

Echt stark heute dieses Momentum

Hat sicher aber schnell wieder erholt 🤠